Edit
Autonomic Technologies Europe
http://www.ati-spg.com/Last activity: 25.06.2015
Active - Reference to Realeve
Autonomic Technologies Europe GmbH is a 100% subsidiary of Autonomic Technologies, Inc. (ATI), a medical device company located in the San Francisco Bay Area focused on the development and commercialization of innovative therapies for the treatment of autonomic disorders, particularly severe headache. The company’s initial product, the Pulsant microstimulator, is CE marked in Europe for the treatment of cluster headache. The device is also under an IDE study in the US for the treatment of chronic cluster headache.
Total raised: $81.2M
Investors 2
| Date | Name | Website |
| - | CRG | crglp.com |
| - | Forbion | forbion.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.06.2015 | Series D | $43.2M | - |
| 12.05.2015 | Series D | $38M | - |
Mentions in press and media 6
| Date | Title | Description |
| 25.06.2015 | Autonomic Technologies Closes $43.2M Series D Financing | Autonomic Technologies, Inc. , a Redwood City, CA-based developer and manufacturer of Pulsante™, a microstimulator to treat severe headaches, raised an additional $5.5M and closed a Series D round of financing at $43.2M. The investment was ... |
| 12.05.2015 | Autonomic Technologies Closes $38M Series D Financing | Autonomic Technologies™, Inc., a Redwood City, California-based developer and manufacturer of a microstimulator to treat severe headaches, closed a $38m Series D financing. The round was led by Edmond de Rothschild Investment Partners (EdRI... |
| 30.05.2014 | Medtech experts say despite “schizophrenia,” the industry’s prognosis is good | “Our product has great value,” he said. “We’re not there yet, but there are some good trends.” Panelists agreed that investors are more cautious and that deals take longer to put together. Capital is harder to come by, and investors can be ... |
| 23.10.2013 | Versant Ventures seeks $250M for next medtech venture capital fund | Directors who will manage the fund listed on the regulatory filing include CFO Robin Praeger; Bradley Bolzon, formerly of Roche and Eli Lilly; VV Co-Founder Samuel Colella; VV Co-Founder Dr. Ross Jaffe, formerly of Brentwood Venture Capital... |
| - | Versant Ventures seeks $250M for next medtech venture capital fund | Though lots of venture capital for medtech has evaporated, Versant Ventures now seeks $250 million for its fifth medtech fund. The venture capital firm, which has strong presence in biotech and medtech, has a diverse California and Minnesot... |
| - | Medtech experts say despite “schizophrenia,” the industry’s prognosis is good | The investment climate for the medtech industry has become more cautious, more focused on short-term results, and wary of increased government regulation. At the same time there are still plenty of opportunities for growth and success, a pa... |